The global cancer biologics market size was valued at USD 130.7 billion in 2025 and is projected to grow from USD 139.46 billion in 2026 to USD 234.29 billion by 2034, registering a CAGR of 6.7% during the forecast period from 2026 to 2034. North America dominated the cancer biologics market with a market share of 41.6% in 2025.
Cancer biologics are medicines made from living organisms or biological materials and used to prevent, diagnose, or treat cancer. They include monoclonal antibodies, immunotherapies, cancer vaccines, and other targeted biological therapies. These treatments can help the immune system recognize cancer cells or target specific molecules involved in cancer growth.
Download a Free Sample To learn more about this report,
Cell-Based Immunotherapies Are Expanding Into Solid Tumors
The cancer biologics market trends show that cell-based immunotherapies are expanding beyond blood cancers into solid-tumor treatment. This transition is supported by the FDA’s 2024 approval of lifileucel, the first tumor-derived autologous T-cell therapy approved for unresectable or metastatic melanoma, with an objective response rate of 31.5% among 73 patients treated at the recommended dose. The result is a broader role for personalized cellular therapies in solid-tumor oncology and greater development of patient-specific treatment approaches.
Antibody-Drug Conjugates Are Expanding Targeted Cancer Treatment
The cancer biologics market trends show that antibody-drug conjugates are expanding targeted cancer treatment by combining tumor-directed antibodies with potent therapeutic payloads. This transition is illustrated by the FDA’s May 2026 approval of pivekimab sunirine, a CD123-directed antibody and alkylating-agent conjugate, with 23 of 33 treatment-naïve patients (69.7%) achieving complete or clinical complete remission in the supporting trial. The result is broader use of antibody-based delivery platforms designed to concentrate therapeutic activity on specific cancer cells.
Rising Cancer Incidence and Expansion of Biomanufacturing Capacity Drive Market
The global cancer burden is creating a large and sustained patient base for biologic therapies, including monoclonal antibodies and other targeted medicines. IARC estimates that 20.6 million people were diagnosed with cancer in 2024, with the annual number projected to reach 34.4 million by 2050, a 67% increase. This expanding treatment population supports demand for biologics used across cancers such as breast, lung, colorectal, and hematological malignancies. The broader patient pool therefore encourages pharmaceutical companies to expand oncology biologic development and commercial supply.
Biomanufacturing capacity is strengthening the supply of oncology biologics by providing additional facilities and production capabilities for complex biological medicines. The FDA selected seven companies in June 2026 for its PreCheck pilot program to support new U.S. pharmaceutical manufacturing facilities and increase domestic production capacity. New and expanded facilities can support products such as monoclonal antibodies through larger-scale cell-culture and purification operations, improving manufacturing availability. This additional production capacity supports the growing oncology pipeline and strengthens the supply base for cancer biologics.
High Development and Manufacturing Costs and Shorter Product Stability Restrain Cancer Biologics Market Expansion
High development and manufacturing costs for cancer biologics arise from complex research, specialized production facilities, controlled processing, and stringent quality requirements. These costs increase treatment prices and can limit affordability, healthcare-provider adoption, and broader patient access.
Shorter product stability increases the need for controlled storage, temperature monitoring, and efficient distribution throughout the biologics supply chain. Higher handling requirements can increase logistics costs and product wastage, particularly in regions with limited cold-chain infrastructure, restricting wider market adoption.
Bispecific Antibody Therapies and Personalized Cancer Vaccines Create New Market Opportunities
Biopharmaceutical companies, antibody developers, and oncology-focused biotechnology firms can expand their portfolios through bispecific antibodies that connect immune cells with cancer targets. Regeneron’s linvoseltamab received FDA approval in July 2025 for relapsed or refractory multiple myeloma, creating revenue avenues through proprietary antibody platforms, licensing, co-development, and specialized oncology therapies.
Biotechnology companies, vaccine developers, and genomic technology providers can develop personalized cancer vaccines based on tumor-specific neoantigens. The FDA identifies neoantigen-based personalized vaccines as an active oncology development area, creating opportunities for vaccine platforms, genomic analysis, manufacturing partnerships, and technology licensing.
Supply Chain Vulnerabilities and Limited Patient Access to Specialized Cancer Care Hinder Cancer Biologics Market Growth
Supply-chain vulnerabilities can disrupt the availability of cancer biologics when manufacturers, distributors, or healthcare systems face shortages or uneven product distribution. In September 2026, WHO identified specific childhood cancer medicines with documented supply gaps, including pegaspargase, asparaginase, dactinomycin, vincristine, and cytarabine, highlighting how supply limitations can restrict treatment availability.
Limited access to specialized cancer care restricts the use of biologics that require specialist diagnosis, treatment selection, administration, and monitoring. WHO reported in 2025 that cancer-treatment capacity varies widely between and within countries, while shortages of trained healthcare workers and limited treatment infrastructure continue to constrain access, particularly in lower-resource settings.
The monoclonal antibodies segment accounted for a share of 58.7% in 2025, supported by their established role in targeted cancer treatment and their ability to selectively act on specific disease-related molecular targets. Their broad use across oncology therapies and increasing integration into personalized treatment approaches reinforce their leading position in the market. The growth factor segment supports treatment-related requirements by helping manage complications associated with cancer and its therapies, while the blood and blood products segment addresses supportive care and transfusion needs. The vaccines and toxoids segment contributes to immunological approaches aimed at cancer prevention and treatment.
The vaccines and toxoids segment is expected to grow at a CAGR of 8.74% during the forecast period 2026-2034, driven by increasing development of cancer-focused immunological therapies and growing interest in approaches that stimulate or strengthen immune responses against cancer. Expansion of research into therapeutic cancer vaccines and related immunological technologies is supporting demand for this segment.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
The North America cancer biologics market accounted for the largest regional share of 41.6% in 2025, supported by advanced oncology infrastructure, high adoption of biologic therapies, strong pharmaceutical and biotechnology research activity, and increasing demand for targeted cancer treatments. The U.S. cancer biologics market is supported by the National Cancer Institute’s projection that annual cancer cases worldwide will reach 33 million by 2050, while the FDA continues expanding oncology biologic approvals and indications, with 19 new medical entities or biologics and 34 new indications approved in 2024, supporting continued demand for advanced cancer biologics.
The Canada cancer biologics market is supported by projections of 254,100 new cancer cases in 2026, while Ontario Health projects cancer cases in Ontario to increase by 25.4% to 115,306 by 2030, supporting sustained demand for advanced cancer treatments, including biologic therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia-Pacific cancer biologics market is expected to grow at a CAGR of 9.36% during the forecast period, showcasing the fastest-growing regional market, supported by rising cancer incidence, expanding healthcare infrastructure, increasing access to advanced biologic therapies, and growing investments in oncology research and precision medicine. The Japan cancer biologics market is supported by the National Cancer Center’s projection that average annual cancer incidence will reach about 1.18 million cases during 2035–2039, while the Ministry of Health, Labour and Welfare expects cancer genomic medicine facilities to expand to around 460 institutions by around 2030, supporting demand for advanced and personalized cancer biologics.
The China cancer biologics market is supported by the government’s target to raise the overall five-year cancer survival rate to 46.6% by 2030, alongside plans to accelerate approval and improve accessibility of innovative anticancer drugs, including novel antibodies and cell and gene therapies, supporting demand for advanced biologic treatments.
The Europe cancer biologics market accounted for a 27.3% share in 2025 and is expected to grow at a CAGR of 7.18% during the forecast period 2026-2034, supported by cancer diagnoses projected to surpass 3.24 million by 2040 and continued EU investment in cancer research, innovation, and advanced treatments. The U.K. cancer biologics market is supported by cancer incidence projected to exceed 500,000 new cases annually by 2040, while the National Cancer Plan aims to deliver up to 10,000 cancer immunotherapies to patients by 2030 and achieve 75% five-year cancer survival by 2035, supporting demand for advanced biologic and immunotherapy treatments.
The Germany cancer biologics market is supported by projections of up to 600,000 new cancer cases annually by 2030, while Germany’s National Cancer Plan continues to prioritize faster access to innovative cancer therapies and stronger digitalization of oncology care, supporting demand for advanced biologic treatments.
The cancer biologics market competitive landscape is moderately consolidated, with competition comprising biopharmaceutical companies, oncology-focused drug developers, biologics manufacturers, immunotherapy developers, and targeted cancer therapy providers. Key players such as Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company, Sanofi, and Bristol-Myers Squibb Company collectively are estimated to account for approximately 45–50% of the global cancer biologics market share.
Established players compete primarily on clinical efficacy, biologics pipeline strength, therapeutic innovation, and manufacturing capabilities. Emerging and specialized players in the cancer biologics market ecosystem compete through targeted therapies, antibody-drug conjugates, immunotherapies, biosimilars, and cell and gene therapies. Roche maintains a broad oncology portfolio spanning immunotherapies, antibody-drug conjugates, and targeted treatments, while Novartis is advancing biologics, radioligand therapies, and cell and gene therapies across oncology indications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com